Isaacson v. Novartis Pharmaceuticals Corporation
Plaintiff: Isaacson and Douglas Isaacson
Defendant: Novartis Pharmaceuticals Corporation
Case Number: ND/3:21-CV-00057
Filed: March 12, 2021
Court: Judicial Panel on Multidistrict Litigation
Presiding Judge: Alice R Senechal
Nature of Suit: Other
RSS RSS Track this Docket
Docket Report

This docket was last retrieved on May 6, 2021. A more recent docket listing may be available from PACER.

Date Filed Document Text
May 6, 2021 Filing 10 RESPONSE IN SUPPORT -- (re: pldg. ( 1 in MDL No. 3006) ) Filed by Plaintiffs Curtis Pederson, #et al.Jeffrey Giancaspro, Douglas Isaacson, PAMELA GUSTIN, TERESA GUSTIN, Randy Poitra, Ronald Hurd, ROBIN DAVIS, Robert Merced, CHARLOTTE DEAN, Sheila Colella, Stephen Lally #[Suppress List] (Attachments: #1 Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3006, CT/3:20-cv-00367, FLM/3:20-cv-00346, FLM/8:20-cv-00587, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/3:20-cv-05216 (Muhlstock, Melanie) CORRECTED NAME OF ATTACH. #1 Modified on 5/7/2021 (CMD).
May 6, 2021 Filing 9 RESPONSE IN OPPOSITION -- (re: pldg. ( 1 in MDL No. 3006), ( 12 in MDL No. 3006)) Filed by Defendant Novartis Pharmaceuticals Corporation (Attachments: #1 Declaration of Andrew L. Reissaus, #2 Exhibit 1 - Letter dated July 20, 2020, #3 Exhibit 2 - Letter dated December 11, 2020, #4 Exhibit 3 - Letter dated December 21, 2020, #5 Exhibit 4 - Letter dated April 23, 2021, #6 Exhibit 5 - Letter dated April 6, 2021, #7 Exhibit 6 - Letter dated April 30, 2021, #8 Exhibit 7 - Email dated March 15, 2021, #9 Exhibit 8 - Email dated April 26, 2021, #10 Exhibit 9 - Email dated April 20, 2021, #11 Exhibit 10 - Email dated April 15, 2021, #12 Exhibit 11 - Excerpts of Deposition taken April 16, 2021, #13 Proof of Service) Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, FLM/8:21-cv-00979, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (Hollingsworth, Joe) ADDED MDL LINK & DELETED DUPLICATE PARTY NAME Modified on 5/7/2021 (CMD).
April 30, 2021 Filing 8 ERRATA - to (6 in ARW/2:20-cv-02032, 7 in CT/3:20-cv-00367, 6 in FLM/2:20-cv-00168, 7 in FLM/3:20-cv-00346, 7 in FLM/8:20-cv-00587, 6 in ILS/3:20-cv-00269, 6 in MD/1:20-cv-01249, #8 in MDL No. 3006, 7 in NCM/1:20-cv-01127, 7 in ND/3:20-cv-00123, 7 in ND/3:21-cv-00057, 4 in NJ/2:20-cv-02753, 7 in NJ/2:20-cv-02755, 7 in NM/2:20-cv-00262, 7 in NYS/1:20-cv-02359, 6 in WAW/2:20-cv-01641, 7 in WAW/3:20-cv-05216, 6 in WAW/3:20-cv-05221, 6 in WIE/2:21-cv-00135), (5 in ARW/2:20-cv-02032, 6 in CT/3:20-cv-00367, 5 in FLM/2:20-cv-00168, 6 in FLM/3:20-cv-00346, 6 in FLM/8:20-cv-00587, 5 in ILS/3:20-cv-00269, 5 in MD/1:20-cv-01249, #7 in MDL No. 3006, 6 in NCM/1:20-cv-01127, 6 in ND/3:20-cv-00123, 6 in ND/3:21-cv-00057, 3 in NJ/2:20-cv-02753, 6 in NJ/2:20-cv-02755, 6 in NM/2:20-cv-00262, 6 in NYS/1:20-cv-02359, 5 in WAW/2:20-cv-01641, 6 in WAW/3:20-cv-05216, 5 in WAW/3:20-cv-05221, 5 in WIE/2:21-cv-00135) - Filed by Defendant Novartis Pharmaceuticals Corporation (Attachments: #1 Proof of Service) Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (Hollingsworth, Joe) DELETED DUPLICATE PARTY NAME Modified on 4/30/2021 (CMD).
April 29, 2021 Filing 7 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 3006) -- Identifying Corporate Parent Novartis Finance Corp., Corporate Parent Novartis Corp., Corporate Parent Novartis AG, Corporate Parent NOVARTIS HOLDING, AG, Non-Party/Financial Interest Novartis AG indirectly owns a 100% interest in NPC for Novartis Pharmaceuticals Corporation. (Attachments: #1 Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (Hollingsworth, Joe) DELETED DUPLICATE PARTY NAME Modified on 4/30/2021 (CMD).
April 29, 2021 Filing 6 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 3006) Filed by Joe Gregory Hollingsworth on behalf of Defendant Novartis Pharmaceuticals Corporation (Attachments: #1 Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (Hollingsworth, Joe) DELETED DUPLICATE PARTY NAME Modified on 4/30/2021 (CMD).
April 29, 2021 Filing 5 NOTICE OF APPEARANCE re: pldg.( #1 in MDL No. 3006) Filed by Melanie H. Muhlstock on behalf of Plaintiffs Curtis Pederson, #et al.Jeffrey Giancaspro, Douglas Isaacson, PAMELA GUSTIN, T ERESA GUSTIN, Randy Poitra, Ronald Hurd, ROBIN DAVIS, Robert Merced, CHARLOTTE DEAN, Sheila Colella, Stephen Lally #[Suppress List] (Attachments: #1 Schedule of Actions, #2 Proof of Service) Associated Cases: MDL No. 3006, CT/3:20-cv-00367, FLM/3:20-cv-00346, FLM/8:20-cv-00587, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/3:20-cv-05216 (Muhlstock, Melanie)
April 15, 2021 Filing 4 ***TEXT ONLY NOTICE***NOTICE OF FILING AND PUBLICATION OF BRIEFING SCHEDULE re: pldg. ( #1 in MDL No. 3006) BRIEFING SCHEDULE IS SET AS FOLLOWS:< br< Notices of Appearance due on or before 4/29/2021. Corporate Disclosure Statements due on or before 4/29/2021. Responses due on or before 5/6/2021. Reply, if any, due on or before 5/13/2021. In their briefs, the parties should address what steps they have taken to pursue alternatives to centralization (including, but not limited to, engaging in informal coordination of discovery and scheduling, and seeking Section 1404 transfer of one or more of the subject cases). #Appearance forms (JPML form 18) and #Corporate Disclosure forms can be downloaded from our website. Important: A Corporate Disclosure Form, if required, must be filed, even if one has previously been filed in this MDL.Please visit the #CM/ECF Filing Guidelines < Forms page of our website for additional information.Signed by Clerk of the Panel John W. Nichols on 4/15/2021. Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02753, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (DP)
April 15, 2021 Filing 3 ***TEXT ONLY ENTRY***MINUTE ORDER REVOKING ORDER (re: pldg. (2 in ARW/2:20-cv-02032, 2 in CT/3:20-cv-00367, 2 in FLM/2:20-cv-00168, 2 in FLM/3:20-cv-00346, 2 in FLM/8:20-cv-00587, 2 in FLM/8:20-cv-02753, 2 in ILS/3:20-cv-00269, 2 in MD/1:20-cv-01249, 3 in MDL No. 3006, 2 in NCM/1:20-cv-01127, 2 in ND/3:20-cv-00123, 2 in ND/3:21-cv-00057, 2 in NJ/2:20-cv-02755, 2 in NM/2:20-cv-00262, 2 in NYS/1:20-cv-02359, 2 in WAW/2:20-cv-01641, 2 in WAW/3:20-cv-05216, 2 in WAW/3:20-cv-05221, 2 in WIE/2:21-cv-00135) )NOTICE OF FILING AND PUBLICATION OF BRIEFING SCHEDULE issued on 4/15/21 is REVOKED. Signed by Clerk of the Panel John W. Nichols on 4/15/2021. Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, FLM/8:20-cv-02753, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (JN)
April 15, 2021 Filing 2 REVOKED SEE PLEADING NO. 5***TEXT ONLY NOTICE***NOTICE OF FILING AND PUBLICATION OF BRIEFING SCHEDULE re: pldg. ( 1 in MDL No. 3006) BRIEFING SCHEDULE IS SET AS FOLLOWS: Notices of Appearance due on or before 4/29/2021. Corporate Disclosure Statements due on or before 4/29/2021. Responses due on or before 5/6/2021. Reply, if any, due on or before 5/13/2021. In their briefs, the parties should address what steps they have taken to pursue alternatives to centralization (including, but not limited to, engaging in informal coordination of discovery and scheduling, and seeking Section 1404 transfer of one or more of the subject cases). #Appearance forms (JPML form 18) and #Corporate Disclosure forms can be downloaded from our website. Important: A Corporate Disclosure Form, if required, must be filed, even if one has previously been filed in this MDL.Please visit the #CM/ECF Filing Guidelines & Forms page of our website for additional information.Signed by Clerk of the Panel John W. Nichols on 4/15/2021. Associated Cases: MDL No. 3006, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-cv-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, FLM/8:20-cv-02753, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (DP) Modified on 4/15/2021 (DP).
April 15, 2021 Filing 1 MDL Number 3006 Assigned -- MOTION FOR TRANSFER ACCEPTED FOR FILING re: pldg. ( #1 in Pending No. 30) Associated Cases: Pending No. 30, ARW/2:20-cv-02032, CT/3:20-cv-00367, FLM/2:20-c v-00168, FLM/3:20-cv-00346, FLM/8:20-cv-00587, FLM/8:20-cv-02753, ILS/3:20-cv-00269, MD/1:20-cv-01249, NCM/1:20-cv-01127, ND/3:20-cv-00123, ND/3:21-cv-00057, NJ/2:20-cv-02755, NM/2:20-cv-00262, NYS/1:20-cv-02359, WAW/2:20-cv-01641, WAW/3:20-cv-05216, WAW/3:20-cv-05221, WIE/2:21-cv-00135 (DP)

Access additional case information on PACER

Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.

Access this case on the Judicial Panel on Multidistrict Litigation's Electronic Court Filings (ECF) System

Search for this case: Isaacson v. Novartis Pharmaceuticals Corporation
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Web [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ]
Defendant: Novartis Pharmaceuticals Corporation
Represented By: Joe Gregory Hollingsworth
Represented By: Robert Johnston
Represented By: Andrew L Reissaus
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Isaacson
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]
Plaintiff: Douglas Isaacson
Represented By: Raymond C Silverman
Represented By: Tatum O'Brien
Represented By: Harrison Macy Biggs
Represented By: Melanie H. Muhlstock
Represented By: Christopher Oxx
Search News [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ]
Search Finance [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ]
Search Web [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ]

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?